Symposium to highlight latest developments in predictive and preventive personal medicine
MENLO PARK, Calif., Nov. 12, 2015 /CNW/ -- Avellino Labs (http://www.avellinolab.com/us/), the global leader in genetic testing for eye care, announced today that it has started commercial testing with the Universal Test at its CLIA certified laboratory in Menlo Park, California, and at its eight other laboratories worldwide. The Universal Test expands from 2 to 5 the number of inherited corneal dystrophies detected by Avellino Labs' Refractive Surgery Safety DNA Test.
To view the Avellino Labs press kit for AAO 2015, please visit
"The best genetic screening tools, like Avellino's DNA test, look for specific defects associated with known conditions and yield insights that help physicians make good, fully informed choices about their patients' medical care," commented John Marshall, PhD FMedSci, Director of The Institute of Ophthalmology in association with Moorfields Eye Hospital, London.
Avellino Labs unique DNA Test for LASIK and Refractive Surgery Safety is patent protected and provides fast, accurate and affordable results. It screens for GCD1, GCD2, LCD1, Reis-Bucklers, and Thiel-Behnke Corneal Dystrophies. Testing is performed in Avellino's CLIA certified lab in Menlo Park, California, and has been qualified as 100% accurate with no false positives in clinical trials. The Avellino DNA Test for LASIK Safety has been recognized as transformative global health technology by The World Economic Forum (WEF), which named Avellino Labs a 2015 Technology Pioneer.
"Advances in human genomics are enabling the development and adoption of more personalized medical care in many areas of medical science. Avellino Labs, as the prime mover in DNA testing for eye care, set the standard for the industry with its test for Granular Corneal Dystrophy and is raising the bar by adding the ability to test for Lattice and two other rare corneal dystrophy variants with the Universal Test," commented Gene Lee, Chairman and Founder of Avellino Labs.
Simultaneously, the company announced that its technology will be featured at an EyeNet sponsored Lunch Symposium*, DNA Testing for Keratorefractive Surgery Safety, with Anthony Aldave, MD (Los Angeles), Jay Bansal, MD (San Francisco), John Marshall, PhD, FMedSci (London), and Fengju Y. Zhang, MD (Beijing), presenting. The event takes place at 12:45 p.m. on Monday, November 16th in Las Vegas at the Venetian Ballroom C in the Sands Expo Center of the Venetian Hotel. In addition, the company will provide opportunities to "Meet the Experts" at its Technical Exhibit (Booth #5036) during American Academy of Ophthalmology (AAO) Annual Meeting in Las Vegas, November 14th to 17th, 2015.
About Avellino Labs
Avellino Labs has developed the first and only commercially available DNA Test for LASIK and Refractive Surgery Safety. The company's proprietary Avellino Genetic Diagnostics System (AGDSTM) provides fast, safe and affordable evaluation of an individual's genetic predisposition to the five most common corneal dystrophies. With the Avellino DNA Test, Avellino Labs is able to positively identify, with high accuracy, a patient's corneal dystrophy status. Based on the test's results, patients and their physician can make an informed decision when considering laser vision correction surgery.
For more information, please contact Scott Korney, COO, Avellino Labs, at email@example.com or +1 650 396 3741
*These programs are non-CME, and the content and speakers are developed completely independently by industry. They are not affiliated with the official program of AAO 2015 or Subspecialty Day. By attending a lunch, you may be subject to reporting under the Physician Payment Sunshine Act.
Scott Korney, COO
SOURCE Avellino Labs